Gepon

Published · Researched 2026-09-21

Overview

Gepon is the brand name of HEP-1, a synthetic 14-amino-acid peptide (TEKKRRETVEREKE) that mimics a receptor-binding site of human ezrin. Registered with the Russian Ministry of Health in 2000 (Reg. R No: 000015/01-2000) as an immunomodulator for mucosal/skin infections (candidal vulvovaginitis, urethritis, cervicitis), intestinal dysbiosis/IBS, and opportunistic infections in HIV patients. English-language publications report its use for STIs (HPV condylomas, syphilis, herpes) and early-COVID volunteer use (sublingual/inhaled solutions with reported rapid fever reduction — Holms et al., UNVERIFIED as clinical evidence).

Social standing

  • Modest, forum-driven signal. The clearest peer discussion is a Phoenix Rising ME/CFS Forums thread ("HEP-1 / Ezrin / Gepon", 2025) where an immunologist suggested Gepon for post-COVID ME and members asked for experiences — a patient-forum signal outside the Meta platforms. COVID-era ezrin-peptide volunteer reports (Holms) add anecdote-level evidence.
  • No Threads/Instagram/Facebook Group discussion found in this pass — Gepon is absent from the 2026 Meta peptide conversation.
  • Recurring praise (where mentioned): unusual topical/sublingual route (not injected); broad-spectrum antiviral/anti-inflammatory claims; IL-6 inhibition narrative.
  • Recurring complaints/failure modes: no Western community; sourcing difficulty; claims rest on Russian literature and small volunteer reports.
  • Representative quotes: none with attributable peer-owner provenance on Meta platforms.

Social validation

Tier 3 / UNVALIDATED on Meta — one independent patient-forum thread (Phoenix Rising) + science-publication anecdotes, but no two independent Meta-platform social sources. Included for research completeness as the only ezrin-derived immunomodulator on this track.

Key specs table

Property Value
Identity Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu (TEKKRRETVEREKE; HEP-1) — confirmed against box label text
Size 14 aa synthetic peptide
Origin Ezrin receptor-site mimic (Holms/Ataullakhanov); Russian production by Immapharma / Russian Peptide / Avexim
Mechanism (reported) Inhibits inflammatory cytokines (notably IL-6); amplifies adaptive antiviral immunity and antibody titers; immunomodulating + anti-inflammatory
Forms Pharma: 2 mg lyophilizate vial (1 vial/box, "ГЕПОН", avexima) for topical/oral solution; topical cream preparations
Community-reported dosing None observed. Russian-label use per literature: e.g. HPV condylomas — 2 mg/2 mL sublingual every other day × 10 (20 mg total) + topical cream 3×/day × 9 weeks (case-series literature, NOT community protocol)

Pricing

  • Russian pharmacy (observed 2026-09-20): listed on apteka.ru (2 mg × 1 vial, avexima) — live price not displayed in this pass (UNVERIFIED).
  • US gray market: no widely listed Gepon vials found (UNVERIFIED/unavailable).
  • Facebook Marketplace: no used listings observed — say so plainly (none found).

What's included / what's needed

Pharma box: 1 vial (2 mg lyophilizate) + Russian insert; diluent (distilled water/saline) sourced separately. Topical prep mixes vial contents with cream base per labeling.

Support reality

Russian/CIS pharmacy distribution (avexima); product site gepon.ru. No Western community infrastructure; buyer guidance is Russian-language labeling and the sparse English literature.

Community verdict

Gepon is a "patient-forum peptide" — its only real Western discussion lives in chronic-illness forums, not peptide social. The mucosal/topical angle makes it genuinely different from the injectable-heavy track, but without a community it's a research-complete placeholder. The STI/HIV/Herpes clinical claims deserve skepticism at volunteer-report level.

Regulatory & safety status

Registered drug in Russia (immunomodulator, since 2000; used for mucosal infections, HIV opportunistic infections, STI-adjacent indications) — NOT FDA-approved, no EMA approval. Any Gepon outside Russia/CIS is unapproved; gray-market products are research chemicals not for human use. Safety signals (observed): Russian labeling reports good tolerability with local use; volunteer COVID reports claim no adverse reactions (UNVERIFIED). Never imply US/EU human-use approval.

Image view breakdown

1/8 views obtained (JPEG, verified 2026-09-20):

  • hero: gepon-hero.jpg (apteka.ru retail photo — avexima ГЕПОН 2 mg box + vial; sequence visible on label) Missing views: side, rear, top, detail, inuse, scale, box — one real photo found; official site (gepon.ru) image fetch timed out.

Not medical advice. This is a research summary of publicly discussed information, not a recommendation to use any substance.

Gepon — hero view
hero view Original vendor page URL not recorded in research dossier

Named sources

  • Holms — COVID-era ezrin-peptide volunteer reports (Holms) add anecdote-level evidence.
  • Phoenix Rising ME/CFS Forum — **Modest, forum-driven signal.** The clearest peer discussion is a Phoenix Rising ME/CFS Forums thread ("HEP-1 / Ezrin / Gepon", 2025) where an immunologist suggested Gepon for post-COVID ME and members asked for experiences — a patient-forum signal outside… (2025)

Source URLs were not recorded for these references.